DiaGenic patent allowed in Canada
DiaGenic has received notice of allowance for its Canadian family 2 patent application. The allowed claims cover the use of a set of gene sequences in blood essential for the diagnosis of, among other diseases, Alzheimer’s disease and stages thereof. The patent when granted will be valid until 2023.
Paul de Potocki, Chief Executive Officer
Telephone: 47 2324 8950
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com